Outcomes from peptic ulcer surgery have not benefited from advances in medical therapy

American Surgeon

Volumn 68, Issue 4, 2002, Pages 385-389

  Towfigh, Shirin ^a   Chandler, Charles ^a   Hines, Oscar J ^a   McFadden, David W ^b  

^a UCLA MEDICAL CENTER   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STEROID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PEPTIC ULCER; PEPTIC ULCER BLEEDING; SURGICAL APPROACH; SURGICAL MORTALITY; TERTIARY HEALTH CARE; TREATMENT INDICATION; TREATMENT OUTCOME; MIDDLE AGED; RETROSPECTIVE STUDY; ULCER PERFORATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036546455     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hale DA, Dubois A. Complications of peptic ulcer disease. In: Snape WJ, ed. Consultations in Gastroenterology. Philadelphia: W.B. Saunders Co, 1996, p 335-44.
2. 2-receptor antagonists and endoscopic hemostasis. Surg Today 1995;25:318-23.
3. Sheeline WE. Glaxo's goal: New wonder cures; the U.S. patent on Zantac, the world's best-selling prescription drug, is running out. Fortune 1989;120:101.
4. Fletcher DR. Peptic disease: Can we afford current management? Aust NZ J Surg 1997;67:75-80.
5. Stabile BE, Passaro EP Jr. Surgery for duodenal and gastric ulcer disease. Adv Surg 1993;26:275-306.
6. Summary of the NIH consensus. Helicobacter pylori in peptic ulcer disease. Md Med J 1994;43:923-4.
7. Borody T, Cole P, Noonan S, et al. Long-term Campylobacter pylori recurrence post-eradication (Abstr). Gastroenterology 1988;94:43.
8. Chen CN, Lee WJ, Lee PH, et al. Surgical treatment of peptic ulcer disease: Changing patterns in the past 40 years. J Formos Med Assoc 1996;95:675-9.
9. 2-reeeptor antagonists. Hepatogastroenterology 1992;39:144-8.
10. Meisner S. Sørensen A, Wille-Jørgensen PA. Peptic ulcer surgery 1976-1978 and 1986-1988. Ugeskr Laeger 1993;155:3828-32.
11. Svanes C, Lie RT, Lie SA, et al. Survival after peptic ulcer perforation: A time trend analysis. J Clin Epidemiol 1996;49:1363-71.
12. McConnell DB, Baba GC, Deveney CW. Changes in surgical treatment of peptic ulcer disease within Veterans Hospital in the 1970s and the 1980s. Arch Surg 1989;124:1164-7.
13. Bliss DW, Stabile BE. The impact of ulcerogenic drugs on surgery for the treatment of peptic ulcer disease. Arch Surg 1991;126:609-12.
14. Jacobs DO, Becker JM. Surgery for peptic ulcer disease: For whom and when. In: Snape WJ, ed. Consultations in Gastroenterology. Philadelphia: W.B. Saunders Co, 1996, p 345-55.
15. Lee WJ, Wu MS, Chen CN, et al. Seroprevalence of Helicobacter pylori in patients with surgical peptic ulcer. Arch Surg 1997;132:430-3.